| Code | CSB-RA872550MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to glenzocimab, designed for research applications targeting glycoprotein VI (GP6). GP6 is a platelet-specific collagen receptor that plays a critical role in platelet activation and thrombus formation. Upon binding to exposed collagen at sites of vascular injury, GP6 initiates intracellular signaling cascades that promote platelet adhesion, aggregation, and stabilization of blood clots. Dysregulated GP6 signaling is implicated in thrombotic disorders including acute ischemic stroke, myocardial infarction, and other cardiovascular diseases.
Glenzocimab is a Fab fragment of a humanized anti-GP6 monoclonal antibody that specifically inhibits GP6-mediated platelet activation without affecting normal hemostasis. As the original/reference drug, glenzocimab is mainly used in the research of the treatment of acute ischemic stroke. This biosimilar provides researchers with a valuable tool for investigating platelet biology, thrombosis mechanisms, and cardiovascular disease pathophysiology. It supports studies examining GP6's role in platelet function, collagen-induced signaling pathways, and potential therapeutic interventions for thrombotic conditions. This antibody enables detailed characterization of GP6-dependent processes in experimental models.
There are currently no reviews for this product.